On June 3, Volcano Fuego in Guatemala erupted in what was the most destructive eruption in its history. Within hours, Kenneth Lim, MD, PhD, attending physician in the MGH Division of Nephrology joined rescue workers with Misión Hispana to provide medical care to those injured.
Explore This Research Lab
Our primary R&D platform focuses on therapeutic strategies for accelerated cardiovascular disease in chronic kidney disease (CKD) and other age-associated conditions. We integrate multidisciplinary approaches at the interface of translational and clinical research for improved patient care.
About the Lab
Kenneth Lim, M.D., Ph.D., M.Phil., F.A.S.N. is a Physician-Scientist at the Division of Nephrology, Massachusetts General Hospital and faculty member at Harvard Medical School. He is a graduate of the University of Cambridge (Christ’s College) and University of Warwick in England. He is a Clinical and Translational Investigator with special interest in innovation, commercialization and translational strategies for taking biological discoveries into successful enterprises and early phase exploratory trials. He leads a portfolio of Clinical and Translational research studies that focuses on accelerated age-related cardiovascular disease, a condition that has earned its place as a leading non-communicable health crisis in both developed and developing nations. In his clinical role, Dr. Lim is an Internist and Nephrologist who has deployed to regions around the world to provide leading medical care and strategic principles to help meet critical needs of victims of humanitarian crises, such as war, poverty and natural disasters.
The major theme of his research is the development of advanced therapeutics for age-associated cardiovascular disease in CKD and other chronic inflammatory conditions. This capitalizes on platforms in his group that accelerate commercialization and entry into early phase trials. His group has an emphasis on multidisciplinary collaboration with projects that draw from an international talent pool. The process of innovation leverages on his relationships and networks with industry and beyond. He spearheads several human tissue translational research studies using multidisciplinary approaches that applies next-generation RNA sequencing technology, targeted proteomics and ex vivo organ culture models:
The CAIN (Cardiac Aging in CKD) study: The study investigates the development of uremic cardiomyopathy and cardiac fibrosis in CKD utilizing a unique and rare collection of explanted human heart tissues collected for research purposes. The resources of the CAIN study now support co-investigators from multiple institutions with a global footprint, led in collaboration with Dr. Tzong-shi Lu at the Renal Division, Brigham and Women’s Hospital.
The VAGE (Vascular Anti-aGing stratEgies) study: The study investigates age-associated arterial changes in CKD. Parallel applanation tonometry and echocardiographic measures allow the linking of clinical outcomes with molecular changes using arterial explants.
The AGE (Ant-aging effects of Klotho) study: The study explores the potential of Klotho-based strategies to prevent or reverse age-associated conditions using several disease platforms in cardiovascular medicine, nephrology and oncology (specifically colorectal cancer). This work is led in collaboration with Dr. Irene Chong at the Institute of Cancer Research (ICR) and The Royal Marsden Hospital in London.
His clinical research focuses on the use of Cardiopulmonary Exercise Testing (CPET) technology, a robust and powerful technology that can accurately and reproducibly assess cardiovascular functional capacity in CKD patients. The potential exists for CPET indices such as VO2Max to be used as a new endpoint for cardiovascular trials in nephrology which can help overcome current challenges in cardio-renal trials methodologies. The technology has already provided new insights into cardiovascular physiology in CKD:
The CAPER (Cardiopulmonary Exercise Testing in Renal Failure and After Kidney Transplantation) study: This is the first prospective study to utilize CPET technology before and after kidney transplantation. This study is performed in collaboration with Dr. Thomas Hiemstra at the Clinical Trials Unit, University of Cambridge and Dr. Daniel Zehnder at North Cumbria University Hospitals NHS Trust, UK.
The Framingham Heart Study and The MGH CPET Cohort: In collaboration with Dr. Greg Lewis at the Division of Cardiology, Massachusetts General Hospital, they lead several studies utilizing these large cohorts with available CPET data to assess cardiovascular functional changes in patients with mild decrements in GFR.